Clinical Research Details

Descriptive Information
Incidence and Survival Outcomes of Sarcoma Subtypes in the Lebanese Population

Hazem Assi


Clinical Research - Epidemiologic and Behavioral Studies  

Juliett Berro
Mohamad Srour
Extension: 7902
Conditions and Keywords
Sarcoma Patients
STS, incidence, outcomes,bone sarcoma
Study Design
N/A: Not Applicable
N/A: Not Applicable
N/A: Not Applicable
N/A: Not Applicable
Eligibility and IRB
Min: 16
In Progress

Although sarcomas are a relatively uncommon group of malignancies, the last few years have brought advances in the understanding of the pathology, clinical behavior and the treatment of this heterogeneous group of tumors. However, due to its heterogeneity, the exact overall incidence of sarcoma and sarcoma subtypes has generally been underestimated. Moreover, most epidemiologic studies of Soft Tissue Sarcoma and/or Bone Sarcoma were performed in the western countries, but none in the developing area of the Middle East Region including Lebanon. In the setting, we aim at determining the incidence of sarcoma in Lebanon based on the Tumor Registry database at the American University of Beirut Medical Center.


The primary objective of this retrospective study is to determine the treatment modalities, and outcomes of Soft tissue sarcoma/Bone sarcoma patients treated at the American University of Beirut Medical Center over the period between 2000 and 2015. We also aim at comparing outcomes of sarcoma patients treated at AUBMC to high-level published literature.

This study will provide more insight on the incidence of soft tissue sarcoma/ bone sarcoma at the American University of Beirut Medical Center, a major referral center in the area, and allow estimating the survival outcomes using the treatment protocols adopted in this institute and comparing them to regional and western literature.

All adult patients (≥16 years old) diagnosed with Soft tissue sarcoma/Bone sarcoma having their data registered at the Tumor Registry Database at the American University of Beirut Medical Center between January 1st  2000  and December 31th  2015 inclusive are included.


All adult patients (≥16 years old) with a Soft tissue sarcoma/Bone sarcoma are included, between January 2000 and December 2015 inclusive.

Patients below the age of 16 are excluded.